

# Maria Teresa Melucci

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3198416/publications.pdf>

Version: 2024-02-01

38  
papers

2,333  
citations

331670

21  
h-index

315739

38  
g-index

38  
all docs

38  
docs citations

38  
times ranked

4220  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma. <i>Oncolmmunology</i> , 2017, 6, e1283462.   | 4.6 | 34        |
| 2  | Phenotype characterization of human melanoma cells resistant to dabrafenib. <i>Oncology Reports</i> , 2017, 38, 2741-2751.  | 2.6 | 22        |
| 3  | What is changing in the adjuvant treatment of melanoma?. <i>Oncotarget</i> , 2017, 8, 110735-110736.  | 1.8 | 2         |
| 4  | Low Levels of Genetic Heterogeneity in Matched Lymph Node Metastases from Patients with Melanoma. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1917-1920.   | 0.7 | 13        |
| 5  | Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 325-332.                   | 1.2 | 32        |
| 6  | Epidemiological and genetic factors underlying melanoma development in Italy. <i>Melanoma Management</i> , 2015, 2, 149-163.  | 0.5 | 3         |
| 7  | Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets. <i>Frontiers in Oncology</i> , 2015, 5, 183.   | 2.8 | 80        |
| 8  | The immune-related role of BRAF in melanoma. <i>Molecular Oncology</i> , 2015, 9, 93-104.   | 4.6 | 28        |
| 9  | Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. <i>Oncolmmunology</i> , 2014, 3, e28780.  | 4.6 | 318       |
| 10 | Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 675-683. | 4.2 | 230       |
| 11 | Unexpected Distribution of <i>cKIT</i> and <i>BRAF</i> Mutations among Southern Italian Patients with Sinonasal Melanoma. <i>Dermatology</i> , 2013, 226, 279-284.  | 2.1 | 36        |
| 12 | Mutations in <i>ERBB4</i> May Have a Minor Role in Melanoma Pathogenesis. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1685-1687.   | 0.7 | 8         |
| 13 | The immune score as a new possible approach for the classification of cancer. <i>Journal of Translational Medicine</i> , 2012, 10, 1.   | 4.4 | 656       |
| 14 | Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells. <i>Oncology Reports</i> , 2011, 25, 1495-502.  | 2.6 | 19        |
| 15 | The susceptibility <i>CDKN2</i> locus may have a role on prognosis of melanoma patients. <i>Annals of Oncology</i> , 2010, 21, 1379-1380.   | 1.2 | 6         |
| 16 | NEMO-binding domain peptide inhibits proliferation of human melanoma cells. <i>Cancer Letters</i> , 2009, 274, 331-336.   | 7.2 | 30        |
| 17 | Targeting Bcl-2 protein in treatment of melanoma still requires further clarifications. <i>Annals of Oncology</i> , 2008, 19, 2092-2093.  | 1.2 | 10        |
| 18 | Molecular Classification of Patients With Malignant Melanoma for New Therapeutic Strategies. <i>Journal of Clinical Oncology</i> , 2007, 25, e20-e21.   | 1.6 | 13        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Issues affecting molecular staging in the management of patients with melanoma. <i>Journal of Cellular and Molecular Medicine</i> , 2007, 11, 1052-1068.   | 3.6 | 27        |
| 20 | Adjuvant treatment of malignant melanoma: Where are we?. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 57, 45-52.   | 4.4 | 10        |
| 21 | Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases. <i>Melanoma Research</i> , 2005, 15, 235-244.   | 1.2 | 50        |
| 22 | Pegylated Arginine Deiminase Treatment of Patients With Metastatic Melanoma: Results From Phase I and II Studies. <i>Journal of Clinical Oncology</i> , 2005, 23, 7660-7668.   | 1.6 | 218       |
| 23 | BRAF Gene Is Somatically Mutated but Does Not Make a Major Contribution to Malignant Melanoma Susceptibility: The Italian Melanoma Intergroup Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 286-292.              | 1.6 | 55        |
| 24 | Prognostic Value of Circulating Melanoma Cells Detected by Reverse Transcriptase-Polymerase Chain Reaction. <i>Journal of Clinical Oncology</i> , 2003, 21, 767-773.   | 1.6 | 91        |
| 25 | Mutation analysis of candidate genes in melanoma-prone families. <i>Melanoma Research</i> , 2003, 13, 571-579.   | 1.2 | 11        |
| 26 | Assessment of genetic instability in melanocytic skin lesions through microsatellite analysis of benign naevi, dysplastic naevi, and primary melanomas and their metastases. <i>Melanoma Research</i> , 2003, 13, 167-170. | 1.2 | 35        |
| 27 | Adjuvant therapy of melanoma: what's new?. <i>Melanoma Research</i> , 2002, 12, 293-296.   | 1.2 | 4         |
| 28 | Clinical Significance of PCR-Positive mRNA Markers in Peripheral Blood and Regional Nodes of Malignant Melanoma Patients. <i>Recent Results in Cancer Research</i> , 2001, 158, 200-203.                                   | 1.8 | 19        |
| 29 | Mobile hospital rooms to fight melanoma. <i>Melanoma Research</i> , 2001, 11, 83-84.   | 1.2 | 1         |
| 30 | Low doses interferon- $\alpha$ in the treatment of high-risk cutaneous melanoma. <i>Annals of Oncology</i> , 2000, 11, 487-490.  | 1.2 | 2         |
| 31 | Epithelioid cell-type melanoma as a prognostic factor of poor response to immunological treatment. <i>Annals of Oncology</i> , 2000, 11, 1504.   | 1.2 | 4         |
| 32 | Cisplatin, dacarbazine, and fotemustine plus interferon $\alpha$ in patients with advanced malignant melanoma. <i>Cancer</i> , 2000, 89, 2630-2636.  | 4.1 | 21        |
| 33 | Sensitivity and specificity of epiluminescence microscopy: evaluation on a sample of 2731 excised cutaneous pigmented lesions. <i>British Journal of Dermatology</i> , 2000, 142, 893-898.                                 | 1.5 | 60        |
| 34 | Definition of the role of chromosome 9p21 in sporadic melanoma through genetic analysis of primary tumours and their metastases. <i>British Journal of Cancer</i> , 2000, 83, 1707-1714.                                   | 6.4 | 40        |
| 35 | Circulating melanoma-associated markers detected by RT-PCR in patients with classic Kaposi's sarcoma. <i>Annals of Oncology</i> , 2000, 11, 635-636.   | 1.2 | 3         |
| 36 | Polymerase Chain Reaction-Based Detection of Circulating Melanoma Cells as an Effective Marker of Tumor Progression. <i>Journal of Clinical Oncology</i> , 1999, 17, 304-304.  | 1.6 | 109       |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 37 | Adjuvant therapy of cutaneous melanoma. <i>Lancet, The</i> , 1999, 353, 328.   | 13.7 | 8         |
| 38 | Epiluminescence microscopy as a useful approach in the early diagnosis of cutaneous malignant melanoma. <i>Melanoma Research</i> , 1998, 8, 529-538. | 1.2  | 25        |